Akero Therapeutics, Inc.

NasdaqGS:AKRO Stock Report

Market Cap: US$1.4b

Akero Therapeutics Management

Management criteria checks 3/4

Akero Therapeutics' CEO is Andrew Cheng, appointed in Sep 2018, has a tenure of 5.67 years. total yearly compensation is $8.83M, comprised of 7.5% salary and 92.5% bonuses, including company stock and options. directly owns 0.67% of the company’s shares, worth $9.19M. The average tenure of the management team and the board of directors is 5.6 years and 5.1 years respectively.

Key information

Andrew Cheng

Chief executive officer

US$8.8m

Total compensation

CEO salary percentage7.5%
CEO tenure5.7yrs
CEO ownership0.7%
Management average tenure5.6yrs
Board average tenure5.1yrs

Recent management updates

Recent updates

Akero Therapeutics' EFX Data Warrants Caution

Apr 03

Akero: Phase 2b NASH Data Bodes Well For Phase 3 SYNCHRONY Program

Mar 04

Akero Therapeutics announces closing of upsized public offering

Sep 19

Akero adds over 100% rallying peers after NASH success

Sep 13

We're Not Very Worried About Akero Therapeutics' (NASDAQ:AKRO) Cash Burn Rate

May 04
We're Not Very Worried About Akero Therapeutics' (NASDAQ:AKRO) Cash Burn Rate

We Think Akero Therapeutics (NASDAQ:AKRO) Can Afford To Drive Business Growth

Jan 15
We Think Akero Therapeutics (NASDAQ:AKRO) Can Afford To Drive Business Growth

Akero Therapeutics (NASDAQ:AKRO) Is In A Good Position To Deliver On Growth Plans

Oct 01
Akero Therapeutics (NASDAQ:AKRO) Is In A Good Position To Deliver On Growth Plans

Akero: Ticking All The Right Boxes In NASH

Sep 23

Akero Therapeutics (NASDAQ:AKRO) Is In A Good Position To Deliver On Growth Plans

Jun 10
Akero Therapeutics (NASDAQ:AKRO) Is In A Good Position To Deliver On Growth Plans

CEO Compensation Analysis

How has Andrew Cheng's remuneration changed compared to Akero Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$9mUS$660k

-US$152m

Sep 30 2023n/an/a

-US$120m

Jun 30 2023n/an/a

-US$116m

Mar 31 2023n/an/a

-US$112m

Dec 31 2022US$10mUS$624k

-US$112m

Sep 30 2022n/an/a

-US$121m

Jun 30 2022n/an/a

-US$110m

Mar 31 2022n/an/a

-US$112m

Dec 31 2021US$4mUS$570k

-US$101m

Sep 30 2021n/an/a

-US$98m

Jun 30 2021n/an/a

-US$95m

Mar 31 2021n/an/a

-US$82m

Dec 31 2020US$5mUS$523k

-US$79m

Sep 30 2020n/an/a

-US$65m

Jun 30 2020n/an/a

-US$59m

Mar 31 2020n/an/a

-US$50m

Dec 31 2019US$5mUS$450k

-US$44m

Sep 30 2019n/an/a

-US$90m

Jun 30 2019n/an/a

-US$86m

Mar 31 2019n/an/a

-US$87m

Dec 31 2018US$1mUS$133k

-US$82m

Compensation vs Market: Andrew's total compensation ($USD8.83M) is above average for companies of similar size in the US market ($USD5.72M).

Compensation vs Earnings: Andrew's compensation has been consistent with company performance over the past year.

CEO

Andrew Cheng (56 yo)

5.7yrs

Tenure

US$8,834,907

Compensation

Dr. Andrew Cheng, MD, PhD, serves as Director of Vera Therapeutics, Inc. since May 2017. He served as Director of Arbutus Biopharma Corporation since August 17, 2019 until May 25, 2022. He served as Chief...

Leadership Team

NamePositionTenureCompensationOwnership
Andrew Cheng
President5.7yrsUS$8.83m0.67%
$ 9.2m
Jonathan Young
Co-Founder5.7yrsUS$3.44m0.41%
$ 5.6m
Timothy Rolph
Co-Founder & Chief Scientific Officer7.1yrsUS$3.49m0.20%
$ 2.7m
William White
Executive VP5.1yrsUS$4.29m0.0057%
$ 78.3k
Catriona Yale
Executive VP & Chief Development Officer5.6yrsUS$3.45m0.046%
$ 636.4k
Patrick Lamy
Senior Vice President of Commercial Strategy1.3yrsno datano data
John Schembri
VP of Finance & Controllerno datano datano data

5.6yrs

Average Tenure

53yo

Average Age

Experienced Management: AKRO's management team is seasoned and experienced (5.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Andrew Cheng
President6.3yrsUS$8.83m0.67%
$ 9.2m
Seth Harrison
Independent Director5.1yrsUS$568.56k0.41%
$ 5.7m
Jane Pritchett Henderson
Independent Director5.1yrsUS$586.06k0%
$ 0
Mark Iwicki
Independent Chairman of the Board5.5yrsUS$606.06k0%
$ 0
Tomas Heyman
Independent Director3.9yrsUS$581.06k0%
$ 0
Graham L. Walmsley
Independent Director5.9yrsUS$578.56k0.0031%
$ 43.2k
Yuan Xu
Independent Director3.1yrsUS$573.56k0%
$ 0
Judy Chou
Independent Director2.8yrsUS$571.06k0%
$ 0

5.1yrs

Average Tenure

57yo

Average Age

Experienced Board: AKRO's board of directors are considered experienced (5.1 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.